Therefore, the reliability of using preoperative CNB as the standard for diagnosing and planning treatment for HER2-low breast cancer, particularly with the potential introduction of ADCs for newly diagnosed cases, remains uncertain. This evidence concerns the gene ERBB2 and breast cancer.